Bajaj Healthcare Share Price Soar 10% to Hit All-Time High – Here’s Why

Bajaj Healthcare share price surged 10.5% on the BSE, reaching an all-time high of ₹744.9 per share. The stock rallied after the company received a recommendation from the Subject Expert Committee (SEC) (Neurology & Psychiatry) of the Central Drugs Standard Control Organisation (CDSCO) to conduct Phase III clinical trials for Cenobamate Tablets.

What is Cenobamate?

Cenobamate is an advanced anti-seizure drug used to treat partial-onset seizures in adults. It works by controlling excessive brain activity, reducing seizure frequency, and improving patient well-being.

Stock Performance & Market Data

At 1:03 PM, Bajaj Healthcare shares were up 6.2% at ₹715.6 per share on the BSE, while the Sensex was up 0.3% at 75,523.48. The company’s market value stood at ₹2,260.10 crore.

• 52-week high: ₹744.9
• 52-week low: ₹265
• 1-year gain: 124% (compared to Sensex’s 4.5% rise)

Phase III Trials and Future Plans

The company will test Cenobamate in doses of 12.5mg, 25mg, 50mg, 100mg, 150mg, and 200mg. Phase III trials are crucial as they assess a drug’s effectiveness, safety, and tolerability in a large group of patients before seeking regulatory approval. If successful, Bajaj Healthcare plans to launch Cenobamate in India and manufacture its Active Pharmaceutical Ingredient (API) in-house.

Company’s Global Presence

Founded in 1993, Bajaj Healthcare specialises in manufacturing Active Pharmaceutical Ingredients (APIs), intermediates, formulations, and nutraceuticals. It operates state-of-the-art facilities catering to both developed and emerging markets and has a strong presence in Europe, the USA, Australia, the Middle East, and South America.

Managing Director’s Statement

Anil Jain, Managing Director of Bajaj Healthcare, expressed excitement about the approval and emphasised the company’s commitment to providing high-quality epilepsy treatments.

Conclusion

With the growing demand for effective epilepsy medications, Bajaj Healthcare’s approval for Phase III trials of Cenobamate marks a significant step. The stock’s strong rally reflects investor confidence in the company’s future growth prospects.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.